Compositions and methods to prevent toxicity of antiinflammatory agents and enhance their efficacy
US8519005B2 · kind B2 · utility
Inventor
Key dates
| Filing date | Mar 16, 2004 |
| Grant date | Aug 27, 2013 |
| Priority date | — |
| Expiry date | Jul 26, 2027 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/519
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Effects of deprenyl or propargylamine compounds (MAO inhibitors) and novel compositions comprising at least one MAO inhibitor and at least one antiinflammatory agent such as nonsteroidal antiinflammatory drugs (NSAIDS), steroids, acetaminophen (COX-3 inhibitors), 5-lipoxygenase inhibitors, leukotriene receptor antagonists, leukotriene A4 hydrolase inhibitors, antihistaminics, histamine 2 receptor antagonists, phosphodiesterase-4 antagonists, cytokine antagonists, CD44 antagonists, antineoplastic agents, 3-hydroxy-3-methylglutaryl coenzyme A inhibitors (statins), estrogens, androgens, antiplatelet agents, antidepressants, Helicobacter pylori inhibitors, proton pump inhibitors, thiazolidinediones, dual-action compounds, combinations of these drugs with other agents, derivatives and metabolites of synthetic and natural antiinflammatory agents. The compounds and compositions protect against gastrointestinal, renal and other toxicities induced by antiinflammatory agents, and enhance the beneficial effects of these drugs. Effects of MAO inhibitors such as 1-deprenyl co-administered with antiinflammatory drugs or chemically attached to antniinflammatory drugs are disclosed. Therapeutic me…
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.